LensGen will review its latest data for the world’s first modular fluid optic IOL in several activities around the American Academy of Ophthalmology (AAO) annual meeting in San Francisco this week. LensGen developed Juvene, which uses biomimetic design principles to emulate the natural crystalline lens and provide a continuous dynamic range of vision from distance to near with high quality optics.
Sumit Garg, MD, will discuss the company’s achievements and patient-centric approach to product development during the Ophthalmology Innovation Summit, (OIS) Anterior Spotlight session on Thursday, October 10. Dr. Garg is Vice Chair of Clinical Ophthalmology & Medical Director at the Gavin Herbert Eye Institute, University of California, Irvine.
Rosa Braga-Mele, MD, will moderate a panel discussion at a LensGen sponsored reception on Friday, October 11 at 6:30 pm. Panelists include: Kerry Assil, MD, Uday Devgan, MD, and Sumit Garg, MD, all of whom have experience implanting the Juvene IOL.
“The Juvene may well be the premium IOL that cataract surgeons and their patients have been waiting for. Its potential to provide excellent range of high-quality vision without the compromises of the currently available premium IOLs has created great interest among surgeons around the world,” Dr. Braga-Mele, Professor of Ophthalmology, Faculty of Medicine at the University of Toronto, said in a company news release.
Eric Donnenfeld, MD, will present 6-month results of its “Grail Study” in the AAO’s Main Cataract Session on October 13 at the Moscone Center in Room 152 at 3:30 pm.
“I’m excited to share the latest results from the Grail Study, which will have 30 patients at 6 months and 15 binocular patients at 1-to-6 months. 100% of the binocular patients have full range of vision and are spectacle free for daily activities. I expect a robust discussion among my colleagues about this potentially transformational technology,” Dr. Donnenfeld, who is the Founding Partner of Ophthalmic Consultants of Long Island, said in the news release.
LensGen is currently in the process of raising $60 million in Series B Financing which it expects to close in the first quarter of 2020. The company believes an FDA study for the approval of the Juvene IOL will begin in the second quarter of 2020.
“LensGen continues to build momentum as a company. We received excellent response at the recent ESCRS and expect more of the same at the AAO. We have developed a truly patient-centric IOL that can positively change cataract surgery in the years to come,” Ramgopal Rao, LensGen Chief Executive Officer, said in the news release.